DDrare: Database of Drug Development for Rare Diseases

3 mg [14c]-a4250 capsule (DrugBank: -)

2 diseases

ID	Disease name (Link within this page)	Number of trials
93	Primary biliary cholangitis [Primary biliary cirrhosis (~Mar 2017)]	1
297	Alagille syndrome	1

93. Primary biliary cholangitis [Primary biliary cirrhosis (~Mar 2017)] [ 230 clinical trials, 215 drugs, (DrugBank: 51 drugs), 34 drug target genes, 107 drug target pathways]

Searched query = "Primary biliary cholangitis", "Primary biliary cirrhosis", "PBC"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 230 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03082937 (ClinicalTrials.gov)	January 31, 2017	27/2/2017	An Open Label, Single-dose, Single Period ADME Study of A4250 in Healthy Subjects	An Open Label, Single-Dose, Single Period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-A4250 in Healthy Male Subjects	Orphan Cholestatic Liver Diseases;Progressive Familial Intrahepatic Cholestasis;Alagille Syndrome;Primary Biliary Cirrhosis	Drug: 3 mg [14C]-A4250 capsule	Albireo	NULL	Completed	30 Years	65 Years	Male	6	Phase 1	United Kingdom

297. Alagille syndrome [ 26 clinical trials, 16 drugs, (DrugBank: 8 drugs), 2 drug target genes, 2 drug target pathways]

Searched query = "Alagille syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 26 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03082937 (ClinicalTrials.gov)	January 31, 2017	27/2/2017	An Open Label, Single-dose, Single Period ADME Study of A4250 in Healthy Subjects	An Open Label, Single-Dose, Single Period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-A4250 in Healthy Male Subjects	Orphan Cholestatic Liver Diseases;Progressive Familial Intrahepatic Cholestasis;Alagille Syndrome;Primary Biliary Cirrhosis	Drug: 3 mg [14C]-A4250 capsule	Albireo	NULL	Completed	30 Years	65 Years	Male	6	Phase 1	United Kingdom